



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 03 May 2022 (#17)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notices

- **Financial Conflict of Interest: All Principal Investigators (PIs) and Key Personnel (KP) of all current NIH grants, direct and subawards, must complete the NIH training and submit the certificate the Grants Management Office)** For all new applications, all PI's & KP must complete the certificate before the application can be submitted to NIH. This is in addition to the FCOI declarations that must be signed.
  - FMHS contact: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)
  - Stellenbosch Campus contact [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za).

Link to the training: [https://grants.nih.gov/grants/policy/coi/tutorial2018/story\\_html5.html](https://grants.nih.gov/grants/policy/coi/tutorial2018/story_html5.html)

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notices of Special Interest

[NOT-AA-22-012](#) Notice of Special Interest: Research on Alcohol and Coronavirus Disease (COVID-19) within the Mission of National Institute on Alcohol Abuse and Alcoholism ([NIAAA](#)). This Notice of Special Interest (NOSI) solicits grant applications that advance understanding of critical interactions between alcohol use, SARS-CoV-2, and COVID-19. A central focus is research that can improve public health by informing responses to the evolving COVID-19 pandemic and its consequences. This notice applies to due dates on or after June 5, 2022, and subsequent receipt dates through March 5, 2024.

[NOT-AI-22-042](#) Notice of Special Interest (NOSI): Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP). The purpose of this Notice is to encourage new applications to

support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention. This Notice also encourages applications to develop once-a-month SR/LA strategies for treatment of latent TB and hepatitis B. It is highly likely that in populations with a high burden of TB and/or hepatitis B, HIV patients receiving LA antiretrovirals often require treatments for these infections. Thus, the development of SR/LA drug products for latent TB and hepatitis B that are compatible with SR/LA antiretrovirals are sorely needed. Preferably, these new SR/LA treatments for latent TB and hepatitis B will have suitable pharmacological and safety profiles to enable co-administration with SR/LA antiretrovirals with similar dosing requirements. This notice applies to due dates on or after September 7, 2022, and subsequent receipt dates through May 7, 2025.

**[NOT-AI-22-043](#) Notice of Special Interest (NOSI): Towards Developing a Cure for HBV in HIV/HBV Co-Infection.**

The purpose of this NOSI is to encourage applications for support of innovative basic, translational, and clinical research to identify and address the unique challenges to achieving HBV cure in the presence of HIV. Research on HIV/HBV co-infection relating to the following areas will be encouraged: (1) immunology; (2) virology; and (3) therapeutics. This notice applies to due dates on or after September 5, 2022, and subsequent receipt dates through May 7, 2025.

**[NOT-AI-22-048](#) Notice of Special Interest (NOSI): Administrative Supplements for Lyme Disease and other Tickborne Illnesses.**

The purpose of this Notice is to highlight NIAID's interest in accepting administrative supplement applications from current NIAID awardees focused on Lyme disease or other tickborne illnesses, including the alpha-gal syndrome. Applications designed to develop preliminary discoveries or to initiate translation of basic science discoveries into new tools for preventing, diagnosing or treating tick-borne diseases are encouraged. Application Due Date: May 23, 2022 by 5:00 PM local time of applicant organization. Only existing NIAID-funded awardees are eligible to apply:

- Parent grant must address a tick-borne infectious disease or alpha-gal syndrome.
- Proposed project period of the supplement cannot extend beyond the project period of the parent award.
- Parent grant may not be in its first or last 12 months of award at the time the supplement is requested.
- Awards in a No Cost Extension (NCE) by the time the supplement would be made are ineligible.
- Supplement may not request funds to add vertebrate animals or human subjects that are not already part of the parent grant.
- Supplements requesting new foreign components are not allowed.

**[NOT-CA-22-083](#) Notice of Special Interest (NOSI): Technologies and Informatics Tools for Cancer Metabolomics.**

This Notice of Special Interest (NOSI) is to alert the community that the National Cancer Institute (NCI) is seeking to support development of innovative technologies and informatics tools for metabolomics research by leveraging ongoing programs. Innovative technologies for cancer metabolomics can be supported through the [Innovative Molecular Analysis Technologies \(IMAT\)](#) program and informatics tools for cancer metabolomics can be supported through the [Informatics Technology for Cancer Research \(ITCR\)](#) program. This notice applies to due dates on or after June 14, 2022, and subsequent receipt dates through December 31, 2024.

**[NOT-DE-22-005](#) Notice of Special Interest: Achieving Tissue Robustness Through Harnessing Immune System Plasticity.**

National Institute of Dental and Craniofacial Research ([NIDCR](#)) announces its interest in encouraging state-of-the-art, systematic research approaches to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations, and to examine immune mechanisms of protection against recurrence of chronic inflammation in response to infectious and autoimmune diseases of dental, oral, and craniofacial (DOC) tissues. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies

that shift the balance between degenerative and regenerative processes toward protection against episodic recurrence and preventative disease management in a patient-specific manner across the lifespan. This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through September 8, 2025.

## Funding Opportunity Announcements (FOA)

### 1. Understanding the role of Gut Immune dysfunction and Gut Microbiome in pathogenesis of Central Nervous System co-morbidities in people living with HIV (R21 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-MH-22-230](#)

**Type:** R21

**Application Due Date:** November 18, 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to support studies to investigate mechanisms by which the gut microbiome and gut immune system modulates the brain functions, circuits, neurotransmitters, signalling pathways and synaptic plasticity in the context of HIV and Anti-retroviral therapy. Exploratory and high-risk research projects are encouraged. Basic, preclinical, and clinical (e.g., pathophysiology or mechanisms) research in domestic and international settings are of interest. No clinical trials will be accepted for this FOA. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

**Budget:** NIMH intends to commit a total of \$1,500,000 in FY 2023 to fund 3-5 awards in response to this FOA. Future year amounts will depend on annual appropriations. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Division for Research Development (DRD)  
Stellenbosch Campus  
2041 Krottoa Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105